Roche: FDA approves Tecentriq for hard-to-treat lung cancer
(CercleFinance.com) - Roche's Tecentriq has become the first immunotherapy approved for the initial treatment of an extensive-stage small cell lung cancer that proves especially difficult to treat.
The US Food and Drug Administration has approved Tecentriq, in combination with chemotherapy, for the first-line treatment of adults with extensive-stage small cell lung cancer.
This approval is based on results from a Phase III study, which showed that Tecentriq, in combination with chemotherapy, helped people live significantly longer compared to chemotherapy alone, with a median overall survival of 12.3 months.
The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared to chemotherapy alone, Roche said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The US Food and Drug Administration has approved Tecentriq, in combination with chemotherapy, for the first-line treatment of adults with extensive-stage small cell lung cancer.
This approval is based on results from a Phase III study, which showed that Tecentriq, in combination with chemotherapy, helped people live significantly longer compared to chemotherapy alone, with a median overall survival of 12.3 months.
The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared to chemotherapy alone, Roche said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.